An experimental Ebola virus vaccine made at UW-Madison will be used in a clinical trial expected to start in Japan in December, the researcher behind the vaccine said last week.

The vaccine, developed in the lab of UW-Madison scientist Yoshihiro Kawaoka, was produced at Waisman Biomanufacturing, a specialized center at the university’s Waisman Center near UW Hospital.

In the phase 1 study in Japan involving 30 participants, 15 people will get a low dose of the vaccine and 15 people will get a high dose, said Kawaoka, who also works at the University of Tokyo. Read the full story here.